JDD in the Media

Topcials in Psoriasis Treatments

By January 21, 2020February 14th, 2020No Comments

Psoriasis is a chronic disease that can affect many areas of the body. The use of topical corticosteroids (TCS) is a common treatment, although long-term safety of TCS remains a concern.

A recent article in Dermatology Times cites a Journal of Drugs in Dermatology study which examines how Topical Halobetsol Propionate 0.01% lotion appears to “safely and quickly improve lower-extremity psoriatic lesions,” over typical TCS treatments.
“A post hoc analysis of data from phase 3 studies investigating the efficacy of halobetasol propionate 0.01% lotion for treating moderate-to-severe plaque psoriasis showed that the topical corticosteroid was associated with rapid improvement, and  findings should help dermatologists with treatment decisions for patients with disease involving leg lesions, said Neal Bhatia, M.D., director of clinical dermatology at Therapeutics Clinical Research, San Diego, and the lead author of the paper.”

At the conclusion of the eight-week treatment, the rate of success was significantly higher for patients randomized  to once-daily treatment with halobetasol 0.01% lotion compared with vehicle-treated controls (P<.001 for both comparisons).

View Article Now

You May Also Like

Featured ArticlesJDD HighlightsJDD in the MediaThe Latest
July 31, 2023

WATCH VIDEO ABSTRACT: Assessing Implicit Bias in Dermatology

Click Here to Watch Video Abstract   Background: Patients with skin of color (SOC), defined as Fitzpatrick skin types IV to VI, and of varying ethnicities are under-represented in dermatology. This…
Atopic DermatitisDermatology RoundupJDD HighlightsJDD in the MediaSkin of ColorThe Latest
July 27, 2023

Dermatology Roundup: Racial Differences in Melanoma Survival Rates, ASA Announces Research Scholar Award Recipients

By Allison Sit A study published in the Journal of the American Academy of Dermatology found men with melanoma – and particularly men with skin of color – are more…
Featured ArticlesJDD HighlightsJDD in the MediaThe Latest
July 20, 2023

JDD in the News: Increased Dose of Adalimumab in Overweight, Obese Patients; Topical for Infantile Hemangiomas

Healio covered a JDD study on the impact of an increased dose of adalimumab in hidradenitis suppurativa patients who are overweight or obese. Researchers from the University of California San…

Leave a Reply